ライフサイエンスコーパス: realtime

1 d with the Abbott RealTime HIV-1 Qual assay (RealTime).

2 23-38]) of 150 participants based on Abbott RealTime.

3 rocess that serves language comprehension in realtime.

4 ed the following Deming regression equation: RealTime = 0.940 (TaqMan) + 0.175 log(10) HCV RNA IU/ml.

5 However, using <12 IU/ml for Abbott RealTime, a similar proportion (74%) would be eligible.

6 In treated patients monitored by RealTime, a VL of 40-49 copies/mL and, to a lesser exten

7 patients with undetectable HCV RNA by Abbott RealTime achieved a sustained virologic response.

8 Realtime alerts of modified systemic inflammatory respon

9 Comparison of 216 samples analyzed by RealTime and TaqMan assays produced the following Deming

10 The LOD of the RealTime and two TaqMan assays was approximately 1.0 log

11 We evaluated the Abbott RealTime (ART) and Roche Cobas TaqMan Hepatitis C virus

12 tracking of material degradation in vivo in realtime, as well as the formation of theranostic nanopa

13 In conclusion, the RealTime assay accurately measured HCV viral loads over

14 rements for most samples and showed that the RealTime assay is able to detect all genotypes with no b

15 RNA as the cutoff, the more sensitive Abbott RealTime assay would identify fewer patients eligible fo

16 t, version 2.0, can act as a template in the RealTime assay, but potential cross-contamination could

17 y established in other studies of the Abbott RealTime assay, to determine eligibility for shortened P

18 opies/ml higher than those determined by the RealTime assay.

19 .072 log10copies/ml higher than those of the RealTime assay.

20 bbott investigational use only RealTime HCV (RealTime) assay using the Abbott m2000 platform and comp

21 NA loads in CVL samples, with the Aptima and RealTime assays detecting 30% and 20%, respectively.

22 NorChip), Aptima HPV (Gen-Probe), and Abbott RealTime assays, the BD HPV test, and CINtec p16(INK4a)

23 served for the two conditions tested for all RealTime assays.

24 2 (CAP/CTM) and Abbott m2000 RealTime HIV-1 (RealTime) assays on all subtype samples.

25 For the qualitative RealTime C. trachomatis/N. gonorrhoeae assay, the overal

26 CT/NG assay (GeneXpert) and the Abbott m2000 RealTime CT (m2000) assay were compared to Amplicor for

27 racteristics of the newly FDA-cleared Abbott RealTime CT/NG assay (where "CT" stands for Chlamydia tr

28 In summary, we conclude that the Abbott RealTime CT/NG assay is an accurate and automated new ad

29 The Abbott RealTime CT/NG assay offers C. trachomatis and N. gonorr

30 ll sensitivity and specificity of the Abbott RealTime CT/NG assay were 92.4% and 99.2% for C. trachom

31 he performance characteristics of the Abbott RealTime CT/NG assay, a multiplex real-time PCR assay, f

32 cimens were tested with the automated Abbott RealTime CT/NG assay, Aptima Combo 2 assay (Gen-Probe),

33 This study was entirely open and received realtime feedback from 40 community members.

34 e performed rapidly and accurately using the realtime GeneSearch BLN Assay.

35 Abbott RealTime had 93.3% sensitivity, 27.3% specificity, and 3

36 The Abbott RealTime HBV assay targets the N-terminal region of the

37 s HBV DNA levels >15 IU/mL, using the Abbott RealTime HBV DNA assay.

38 BV) quantification were assessed: the Abbott RealTime HBV IUO, the Roche Cobas AmpliPrep/Cobas TaqMan

39 s AmpliPrep/CobasTaqMan (CAP/CTM) and Abbott RealTime HCV (ART) assays.

40 ation of the Abbott investigational use only RealTime HCV (RealTime) assay using the Abbott m2000 pla

41 ere compared to quantification by the Abbott RealTime HCV assay.

42 s also similarly misquantified by the Abbott RealTime HCV assay.

43 e Roche COBAS TaqMan HCV test and the Abbott RealTime HCV assay.

44 Viral Load assay in comparison to the Abbott RealTime HCV assay.

45 The Abbott RealTime HCV Genotype II RUO (research use only) assay w

46 che High Pure System/Cobas TaqMan and Abbott RealTime HCV RNA assays and the impacts of different HCV

47 those tested retrospectively with the Abbott RealTime HCV RNA test (ART).

48 and finger-stick collection with the Abbott RealTime HCV Viral Load assay (gold standard).

49 at the primer and probe binding sites of the RealTime HCV viral load assay are highly conserved and t

50 (n = 25), Cobas TaqMan v2.0 (n = 11), Abbott RealTime HIV-1 (n = 23), Versant HIV-1 RNA bDNA 3.0 (n =

51 TaqMan HIV-1 v.2 (CAP/CTM) and Abbott m2000 RealTime HIV-1 (RealTime) assays on all subtype samples.

52 ir-resistant specimens were determined using RealTime HIV-1 and Roche Monitor (v1.5).

53 /Cobas TaqMan HIV-1 test (RT) and the Abbott RealTime HIV-1 assay (AR), that utilize real-time PCR ha

54 of HIV-1 viral load results using the Abbott RealTime HIV-1 assay and (ii) evaluate the effect of who

55 ant results were observed between the Abbott RealTime HIV-1 assay and the COBAS AmpliPrep/COBAS TaqMa

56 le in the two groups, demonstrating that the RealTime HIV-1 assay can tolerate raltegravir-selected m

57 Quant Dx assay in comparison with the Abbott RealTime HIV-1 assay using plasma and cervicovaginal lav

58 viral load results as measured by the Abbott RealTime HIV-1 assay.

59 te quantification of HIV-1 RNA in the Abbott RealTime HIV-1 assay.

60 sign strategy was demonstrated in the Abbott RealTime HIV-1 assay.

61 results from the Versant bDNA 3.0 and Abbott RealTime HIV-1 differed by greater than 0.5log10.

62 e specimens were also tested with the Abbott RealTime HIV-1 Qual assay (RealTime).

63 an (CAP/CTM) HIV-1 Qual test, and the Abbott RealTime HIV-1 Qualitative assay.

64 Amplicor Monitor, v1.5 (Monitor), the Abbott RealTime HIV-1 test on the m2000 system (Abbott), and th

65 Monitor v1.5 showed a tendency of the Abbott RealTime HIV-1 to under-estimate results while the TaqMa

66 The Abbott RealTime HIV-1 viral load assay uses primers and probes

67 ntra and inter-assay variation of the Abbott RealTime HIV-1 were 2.95% (range 2.0-5.1%) and 5.44% (ra

68 Bias data comparing the Abbott RealTime HIV-1, TaqMan v2.0 to the Amplicor Monitor v1.5

69 the High Pure System or <12 IU/ml by Abbott RealTime; however, 92% of the patients with undetectable

70 The Abbott RealTime human immunodeficiency virus type 1 (HIV-1) ass

71 , including the ability to provide very fast realtime in situ analyses.

72 High Pure System and reanalyzed using Abbott RealTime (limits of detection, 15.1 IU/ml versus 8.3 IU/

73 say was evaluated using the automated Abbott RealTime m2000 system.

74 y chi (omega, T), a general KWW form for the realtime magnetic relaxation, and a divergence of the mi

75 ay showed positive results for all DBS while RealTime missed five DBS with low target concentrations.

76 The Abbott RealTime MTB assay is a nucleic acid amplification test

77 properties indicate a potential utility for realtime,multi-input processing of distributed sensory d

78 A quantitative reverse-transcriptase RealTime PCR (qRT) assay was developed for these MAAs to

79 nd deconvolution microscopy and quantitative realtime PCR, we found that initiation and elongation oc

80 luding OSX, DMP1, and Wnt3a, was observed by realtime PCR.

81 eptor (MET) were assessed using quantitative realtime polymerase chain reaction on a cohort of 64 liv

82 aft cytokine mRNA production was analyzed by realtime polymerase chain reaction on day 14 after trans

83 We show realtime quantitative detection of a single-copy gene, K

84 qMan assay results were 100% concordant with RealTime results in EDTA plasma samples and in 100 HIV-1

85 sults fell within 0.5 log of the CAP/CTM and RealTime results, respectively.

86 strated results with >1-log differences from RealTime results.

87 We hypothesized that a quantitative realtime reverse transcriptase polymerase chain reaction

88 atory genes in early T-cell precursors using realtime RT-PCR.

89 The Abbott RealTime (RT) HCV assay targets the 5' untranslated regi

90 log(10) RNA IU/ml and was consistent across RealTime's dynamic range of nearly 7 log(10) HCV RNA IU/

91 s AmpliPrep/Cobas TaqMan test and the Abbott RealTime test, are FDA cleared for use with EDTA plasma.

92 CAP/CTM values for subtypes F and G and than RealTime values for subtypes C, F, and G and CRF02_AG.

93 CAP/CTM values and 0.30 log higher than the RealTime values, and the values were >0.4 log higher tha

94 e for shorter treatment duration with Abbott RealTime versus 72% with the High Pure System.

95 dard condition results were observed for all RealTime viral load assays evaluated in this study, with